Skip to main content
Premium Trial:

Request an Annual Quote

Dyadic Raises $3M from Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dyadic International today announced it has raised $3 million from a completed private placement with two unnamed investors.

The proceeds will be used for working capital, including for R&D, and general corporate purposes, the Jupiter, Fla., company said in a statement.

The notes, which will pay interest quarterly at a rate of 8 percent annually, are convertible at the holder's option after Jan. 1, 2011 into shares of Dyadic's common stock. The conversion price is $1.82, 120 percent of the company's average share price for the 30 days prior to the closing date. The notes mature on Jan. 1, 2013.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.